Welcome to our dedicated page for Danaher Corporation news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher Corporation stock.
Danaher Corporation (NYSE: DHR) drives innovation in life sciences, diagnostics, and industrial technologies through cutting-edge scientific instruments and operational excellence. This page serves as a centralized hub for all official company announcements, press releases, and market-moving developments.
Investors and industry professionals will find timely updates on earnings reports, strategic acquisitions, and product innovations that shape Danaher's leadership across healthcare and industrial markets. Our curated news collection simplifies tracking regulatory filings, partnership announcements, and operational milestones.
Key content categories include quarterly financial results, R&D breakthroughs in diagnostic systems, and updates from Danaher's core segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Bookmark this page to stay informed about developments impacting the company's position in precision medicine and industrial automation.
Danaher (NYSE: DHR) reported its Q4 and full-year 2024 results, showing mixed performance. In Q4 2024, revenues increased 2.0% year-over-year to $6.5 billion, with non-GAAP core revenue up 1.0%. Q4 net earnings reached $1.1 billion, or $1.49 per diluted share, with non-GAAP adjusted EPS of $2.14.
For full-year 2024, the company reported flat revenues at $23.9 billion, while non-GAAP core revenue decreased 1.5%. Net earnings were $3.9 billion, or $5.29 per diluted share, with non-GAAP adjusted EPS of $7.48. Operating cash flow was strong at $6.7 billion, with free cash flow of $5.3 billion.
Looking ahead to 2025, Danaher expects Q1 core revenue to decline low-single digits year-over-year, but projects full-year core revenue growth of approximately 3%.
Aldevron has launched Alchemy™, a revolutionary cell-free DNA technology for research grade applications. This innovative technology cuts linear DNA manufacturing time by over 50 percent while producing cleaner, safer DNA templates for mRNA synthesis.
The technology utilizes rolling circle amplification for DNA template production, eliminating the need for cells in DNA amplification. Key benefits include faster turnaround times, lower endotoxin levels, reduced host cell-derived impurities, and high-quality control specifications. The research grade version is currently available to support development and preclinical programs, with a cGMP offering planned for 2025 to support clinical applications.
Beckman Coulter Diagnostics has launched new Research Use Only (RUO) blood-based biomarker immunoassays for neurodegenerative disease research. The assays are designed to assess four key biomarkers: p-Tau217, GFAP, NfL, and APOE ε4, which are important in neurodegenerative diseases research and clinical trials.
The assays are available on the DxI 9000 Immunoassay Analyzer, featuring Lumi-Phos PRO substrate for high-sensitivity testing. GFAP, NfL, and APOE ε4 assays are also available on the Access 2 Immunoassay Analyzer. The APOE ε4 immunoassay offers over 99% concordance with PCR genotyping in just 20 minutes.
These automated, high-throughput platforms aim to improve workflow, precision, and reliability of biomarker testing for neurodegenerative diseases, potentially enabling broader multi-center research collaborations.
Danaher (NYSE: DHR) has announced that CEO Rainer M. Blair will discuss the company's Q4 2024 performance at the J.P. Morgan Healthcare Conference. The company expects Q4 2024 revenues to show a low-single digit percent increase year-over-year. The estimated non-GAAP core revenue for Q4 2024 is projected to be flat year-over-year, surpassing previous guidance which had anticipated a low-single digit percent decline. The company will hold its Q4 and full year 2024 earnings conference call on January 29, 2025.
Danaher (NYSE: DHR) has announced an investment partnership with Innovaccer Inc., a healthcare AI company, through its subsidiaries Danaher Diagnostics and Danaher Ventures. The partnership aims to enhance patient outcomes through digital and diagnostic solutions.
Innovaccer has developed software solutions that create unified patient records to identify care gaps and at-risk patients. The collaboration seeks to accelerate precision diagnostics adoption among clinicians and population health teams, supporting value-based care initiatives.
The partnership aligns with Danaher's mission to advance precision medicine through AI-enabled diagnostics, focusing on providing healthcare providers with data and analytics for faster clinical insights at the point of need.
Danaher (NYSE: DHR) has announced its participation in the upcoming J.P. Morgan Healthcare Conference in San Francisco. The company's President and CEO, Rainer M. Blair, will deliver a presentation on Tuesday, January 14, 2025 at 11:15 a.m. PT.
The presentation will be accessible to the public through a simultaneous webcast, which can be viewed on Danaher's website in the 'Investors' section under 'Events & Presentations' at www.danaher.com.
Danaher (NYSE: DHR) has announced its upcoming fourth quarter 2024 earnings conference call, scheduled for Wednesday, January 29, 2025, at 8:00 a.m. ET. The hour-long call will discuss financial performance and future expectations.
The presentation will be accessible through a webcast on Danaher's website's 'Investors' section under 'Events & Presentations.' Participants can join via phone by dialing 800-445-7795 (U.S.) or +1 785-424-1699 (international).
The earnings press release and presentation materials will be available on the company's website at 6:00 a.m. ET on the call date. A replay will be accessible until February 12, 2025, through both the website and dial-in options.
Danaher (NYSE: DHR) has announced that its Board of Directors approved a regular quarterly cash dividend of $0.27 per share of common stock. The dividend will be paid on January 31, 2025 to shareholders who are registered as holders of record on December 27, 2024.
Danaher (NYSE: DHR) has announced that their President and CEO, Rainer M. Blair, will deliver a presentation at the Evercore ISI HealthCONx Conference. The event is scheduled to take place in Coral Gables, Florida on Wednesday, December 4, 2024, at 3:25 p.m. ET. Interested parties can access a simultaneous webcast of the presentation through the company's website at www.danaher.com.
Danaher (NYSE: DHR) reported its third quarter 2024 results, with net earnings of $818 million, or $1.12 per diluted common share. Non-GAAP adjusted diluted net earnings per common share were $1.71. Revenues increased 3.0% year-over-year to $5.8 billion, while non-GAAP core revenue increased 0.5%. Operating cash flow was $1.5 billion, and non-GAAP free cash flow was $1.2 billion.
CEO Rainer M. Blair highlighted strong performance, particularly in the bioprocessing business, and noted Cepheid's market share gains in molecular testing. For Q4 2024, Danaher anticipates non-GAAP core revenue to decline low-single digits year-over-year. The full year 2024 outlook remains unchanged, with non-GAAP core revenue expected to be down low-single digits year-over-year.
FAQ
What is the current stock price of Danaher Corporation (DHR)?
What is the market cap of Danaher Corporation (DHR)?
